Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other Accumulated Expenses (2023 - 2025)

Contineum Therapeutics has reported Other Accumulated Expenses over the past 3 years, most recently at $1.2 million for Q3 2025.

  • Quarterly results put Other Accumulated Expenses at $1.2 million for Q3 2025, up 1295.24% from a year ago — trailing twelve months through Sep 2025 was $1.2 million (up 1295.24% YoY), and the annual figure for FY2024 was $3.2 million, up 103.82%.
  • Other Accumulated Expenses for Q3 2025 was $1.2 million at Contineum Therapeutics, down from $1.7 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for CTNM hit a ceiling of $3.2 million in Q4 2024 and a floor of $52000.0 in Q2 2024.
  • Median Other Accumulated Expenses over the past 3 years was $1.6 million (2023), compared with a mean of $1.5 million.
  • Peak annual rise in Other Accumulated Expenses hit 3142.31% in 2025, while the deepest fall reached 31.51% in 2025.
  • Contineum Therapeutics' Other Accumulated Expenses stood at $1.5 million in 2023, then soared by 103.82% to $3.2 million in 2024, then tumbled by 62.81% to $1.2 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $1.2 million (Q3 2025), $1.7 million (Q2 2025), and $2.5 million (Q1 2025) per Business Quant data.